<b>IDIX 2009 Clinical Goals</b> [Various updates of which the most consequential is the guidance for a NVS decision by year-end on whether to license IDX184.] <u>HCV</u> Mid 2009: Complete IDX184 monotherapy study. Mid 2009: <b>Start IDX184 phase-2a combination study</b> (SoC ± IDX184). Mid 2009: File IND for IDX375 non-nucleoside polymerase inhibitor. Late 2009: File IND for one of the IDX136/IDX316 protease inhibitors. End 2009: <b>Decision by NVS on whether to license IDX184</b>. <u>HIV</u> Timing unknown (it’s up to the GSK-PFE JV): <b>Start IDX899 phase-2 head-to-head trial vs Sustiva</b>.